Literature DB >> 23219298

Mitochondria as a therapeutic target in heart failure.

Marina Bayeva1, Mihai Gheorghiade, Hossein Ardehali.   

Abstract

Heart failure is a pressing public health problem with no curative treatment currently available. The existing therapies provide symptomatic relief, but are unable to reverse molecular changes that occur in cardiomyocytes. The mechanisms of heart failure are complex and multiple, but mitochondrial dysfunction appears to be a critical factor in the development of this disease. Thus, it is important to focus research efforts on targeting mitochondrial dysfunction in the failing heart to revive the myocardium and its contractile function. This review highlights the 3 promising areas for the development of heart failure therapies, including mitochondrial biogenesis, mitochondrial oxidative stress, and mitochondrial iron handling. Moreover, the translational potential of compounds targeting these pathways is discussed.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219298      PMCID: PMC3594689          DOI: 10.1016/j.jacc.2012.08.1021

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  150 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Regulation of mitochondrial processes: a target for heart failure.

Authors:  Suresh Selvaraj Palaniyandi; Xin Qi; Gouri Yogalingam; Julio Cesar Batista Ferreira; Daria Mochly-Rosen
Journal:  Drug Discov Today Dis Mech       Date:  2010

3.  EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and ameliorates pressure overload-induced heart failure in the harlequin mouse mutant.

Authors:  Vanessa P M van Empel; Anne T Bertrand; Ralph J van Oort; Roel van der Nagel; Markus Engelen; Harold V van Rijen; Pieter A Doevendans; Harry J Crijns; Susan L Ackerman; Wim Sluiter; Leon J De Windt
Journal:  J Am Coll Cardiol       Date:  2006-07-25       Impact factor: 24.094

Review 4.  Targeting AMPK for cardiac protection: opportunities and challenges.

Authors:  Maengjo Kim; Rong Tian
Journal:  J Mol Cell Cardiol       Date:  2010-12-13       Impact factor: 5.000

Review 5.  Nitric oxide synthase in post-ischaemic remodelling: new pathways and mechanisms.

Authors:  Boris Manoury; Virginie Montiel; Jean-Luc Balligand
Journal:  Cardiovasc Res       Date:  2012-01-06       Impact factor: 10.787

6.  Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction.

Authors:  Carola Doerries; Karsten Grote; Denise Hilfiker-Kleiner; Maren Luchtefeld; Arnd Schaefer; Steven M Holland; Sajoscha Sorrentino; Costantina Manes; Bernhard Schieffer; Helmut Drexler; Ulf Landmesser
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

7.  The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.

Authors:  Edward J Gane; Frank Weilert; David W Orr; Geraldine F Keogh; Michael Gibson; Michelle M Lockhart; Christopher M Frampton; Kenneth M Taylor; Robin A J Smith; Michael P Murphy
Journal:  Liver Int       Date:  2010-05-18       Impact factor: 5.828

8.  Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice.

Authors:  Shouji Matsushima; Tomomi Ide; Mayumi Yamato; Hidenori Matsusaka; Fumiyuki Hattori; Masaki Ikeuchi; Toru Kubota; Kenji Sunagawa; Yasuhiro Hasegawa; Tatsuya Kurihara; Shinzo Oikawa; Shintaro Kinugawa; Hiroyuki Tsutsui
Journal:  Circulation       Date:  2006-04-03       Impact factor: 29.690

9.  The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload.

Authors:  Janice M Huss; Ken-ichi Imahashi; Catherine R Dufour; Carla J Weinheimer; Michael Courtois; Atilla Kovacs; Vincent Giguère; Elizabeth Murphy; Daniel P Kelly
Journal:  Cell Metab       Date:  2007-07       Impact factor: 27.287

10.  Sex-specific pathways in early cardiac response to pressure overload in mice.

Authors:  Henning Witt; Carola Schubert; Juliane Jaekel; Daniela Fliegner; Adam Penkalla; Klaus Tiemann; Joerg Stypmann; Stefan Roepcke; Sebastian Brokat; Shokoufeh Mahmoodzadeh; Eva Brozova; Mercy M Davidson; Patricia Ruiz Noppinger; Christian Grohé; Vera Regitz-Zagrosek
Journal:  J Mol Med (Berl)       Date:  2008-07-30       Impact factor: 4.599

View more
  132 in total

Review 1.  Successful aging: Advancing the science of physical independence in older adults.

Authors:  Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor
Journal:  Ageing Res Rev       Date:  2015-10-14       Impact factor: 10.895

Review 2.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 3.  The vulnerable phase after hospitalization for heart failure.

Authors:  Stephen J Greene; Gregg C Fonarow; Muthiah Vaduganathan; Sadiya S Khan; Javed Butler; Mihai Gheorghiade
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 4.  Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies.

Authors:  Anne A Knowlton; Le Chen; Zulfiqar A Malik
Journal:  J Cardiovasc Pharmacol       Date:  2014-03       Impact factor: 3.105

Review 5.  Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials.

Authors:  Kunal N Bhatt; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2018-06

Review 6.  Novel Insights and Treatment Strategies for Right Heart Failure.

Authors:  Weiqin Lin; Ai-Ling Poh; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2018-06

7.  Hydrogen sulfide regulates cardiac mitochondrial biogenesis via the activation of AMPK.

Authors:  Yuuki Shimizu; Rohini Polavarapu; Kattri-Liis Eskla; Chad K Nicholson; Christopher A Koczor; Rui Wang; William Lewis; Sruti Shiva; David J Lefer; John W Calvert
Journal:  J Mol Cell Cardiol       Date:  2018-02-03       Impact factor: 5.000

8.  Estimated Glomerular Filtration Rate and 6-Minute Walk Distance in African Americans with Mild to Moderate Heart Failure.

Authors:  Karen M Vuckovic; Houry Puzantian
Journal:  Cardiorenal Med       Date:  2017-05-24       Impact factor: 2.041

9.  Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling.

Authors:  Katia M S Gomes; Juliane C Campos; Luiz R G Bechara; Bruno Queliconi; Vanessa M Lima; Marie-Helene Disatnik; Paulo Magno; Che-Hong Chen; Patricia C Brum; Alicia J Kowaltowski; Daria Mochly-Rosen; Julio C B Ferreira
Journal:  Cardiovasc Res       Date:  2014-05-09       Impact factor: 10.787

10.  cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury.

Authors:  Ryan M Whitaker; Lauren P Wills; L Jay Stallons; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2013-09-16       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.